Rizwan Romee
Harvard University
Internal medicineSurgeryOncologyHuman leukocyte antigenImmunologyHazard ratioCyclophosphamideHematopoietic stem cell transplantationLeukemiaMyeloid leukemiaGraft-versus-host diseaseBone marrowStem cellTransplantationHematopoietic cellCancer researchMedicineBiologyCumulative incidenceGastroenterology
Publications 202
#1Eric Huselton (URMC: University of Rochester Medical Center)H-Index: 3
#2Michael P. Rettig (WashU: Washington University in St. Louis)H-Index: 29
Last. Mark A. Schroeder (WashU: Washington University in St. Louis)H-Index: 46
view all 13 authors...
Abstract null null Leukemia stem cells utilize cell adhesion molecules like CXCR4/CXCL12 to home to bone marrow stromal niches where they are maintained in a dormant, protected state. Dociparstat sodium (DSTAT, CX-01) is a low anticoagulant heparin with multiple mechanisms of action, including inhibition of the CXCR4/CXCL12 axis, blocking HMGB1, and binding platelet factor 4 (PF-4). We conducted a pilot study adding DSTAT to azacitidine for patients with AML or MDS unresponsive to or relapsed af...
#1Mary Nauffal (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 3
#2Haesook T. Kim (Harvard University)H-Index: 74
Last. Vincent T. Ho (Harvard University)H-Index: 98
view all 11 authors...
Hepatic veno-occlusive disease or sinusoidal obstructive syndrome (VOD/ SOS) is a life-threatening complication of hematopoietic stem cell transplantation (HSCT). Defibrotide is the only FDA-approved medication for the management of severe VOD/ SOS after HSCT. We report our center's experience with commercially available defibrotide as treatment for patients with VOD/SOS. We retrospectively identified 28 cases of VOD/ SOS, based on the European Society for Blood and Marrow Transplantation criter...
#1Jacqueline S. Garcia (Harvard University)H-Index: 16
#2Haesook T. Kim (Harvard University)H-Index: 74
Last. Joseph H. Antin (Harvard University)H-Index: 135
view all 25 authors...
Adding the selective BCL-2 inhibitor venetoclax to reduced intensity conditioning (RIC) chemotherapy (fludarabine and busulfan, FluBu2) may enhance anti-leukemic cytotoxicity and thereby reduce the risk of post-transplant relapse. This phase 1 study investigated the recommended phase 2 (RP2D) of venetoclax, a BCL-2 selective inhibitor, when added to FluBu2 in adult patients with high risk acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and MDS/myeloproliferative neoplasms (MPN) un...
#1Katie Maurer (Harvard University)H-Index: 1
#2Haesook T. Kim (Harvard University)H-Index: 74
Last. Mahasweta Gooptu (Harvard University)H-Index: 10
view all 18 authors...
We sought to evaluate the impact of cryopreservation of unrelated donor peripheral blood stem cell (PBSC) grafts on engraftment, chimerism, and immune reconstitution in the context of the Covid-19 pandemic. We reviewed stem cell product characteristics and clinical outcomes in 101 patients receiving cryopreserved PBSCs from unrelated donors (URD) between January 1, 2019, and December 31, 2020, compared with 203 patients receiving fresh URD PBSCs. We observed no differences in 6-month overall sur...
#6Mohamed A. Kharfan-Dabaja (Mayo Clinic)H-Index: 19
ABSTRACT null null Background: There is increasing use of post-transplant cyclophosphamide (PTCy) for GVHD prophylaxis for both haploidentical and fully matched transplants. Published studies have reported an increased incidence of CMV infection with the use of PTCy. Limited data exist regarding the incidence and outcomes of infection with non-CMV herpes viruses (NCHV) in this setting. null Objective: The aim of this study was to evaluate the cumulative incidence of NCHV infections and the assoc...
#1Kuo-Kai Chin (Brigham and Women's Hospital)
#2Haesook T. Kim (Harvard University)H-Index: 74
Last. Robert J. Soiffer (Harvard University)H-Index: 127
view all 13 authors...
Structured Abstract null null Background null Chronic graft-versus-host disease (cGVHD) is a leading cause of late morbidity and mortality after allogenic hematopoietic stem cell transplantation. Corticosteroid-based therapies are a mainstay of its initial treatment but there is no consensus in how to treat steroid-refractory cGVHD. Ibrutinib is a Bruton Tyrosine Kinase and Interleukin-2 Inducible Kinase inhibitor thought to affect pathways driving cGVHD, and it was approved for the treatment of...
#1Roman M Shapiro (Harvard University)H-Index: 2
#2Grace Birch (Harvard University)
Last. Yohei Arihara (Harvard University)H-Index: 7
view all 28 authors...
Abstract null Background null Responses to conventional donor lymphocyte infusion (DLI) for post-allogeneic hematopoietic cell transplantation (HCT) relapse are typically poor. Natural killer (NK) cell-based therapy is a promising modality to treat post-HCT relapse. null Methods null We initiated this ongoing phase 1 trial of adoptively transferred cytokine induced memory-like (CIML) NK cells in patients with myeloid malignancies relapsed after haploidentical HCT. All patients received a donor-d...
#3Erin M. Parry (Harvard University)H-Index: 9
#1Mohamed A. Kharfan-Dabaja (Mayo Clinic)H-Index: 19
Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for certain hematologic malignancies and nonmalignant diseases. The field of allo-HCT has witnessed significant advances, including broadening indications for transplantation, availability of alternative donor sources, less toxic preparative regimens, new cell manipulation techniques, and novel GVHD prevention methods, all of which have expanded the applicability of the procedure. These advances have led to clinical...
#1Mahasweta Gooptu (Harvard University)H-Index: 10
#2Rizwan Romee (Harvard University)H-Index: 25
Last. Ephraim J. Fuchs (Johns Hopkins University)H-Index: 61
view all 27 authors...
Post transplant cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis has allowed haploidentical (Haplo) transplantation to be performed with results similar to that after matched unrelated donor (MUD) transplantation with traditional prophylaxis. The relative value of transplantation with MUD versus Haplo donors when both groups receive PTCy/calcineurin inhibitor/mycophenolate containing GVHD prophylaxis is not known. We compared outcomes after 2036 Haplo and 284 MUD transplantat...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.